Biomedical Engineering Reference
In-Depth Information
REFERENCES
10. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O,
Akslen LA, et al. (2009) Combined vascular endothelial growth
factor receptor and epidermal growth factor receptor (EGFR)
blockade inhibits tumor growth in xenograft models of EGFR
inhibitor resistance. Clin. Cancer Res. 15(10), 3484-3494.
11. Pakkala S, Ramalingam SS. (2009) Combined inhibition of
vascular endothelial growth factor and epidermal growth factor
signaling in non-small-cell lung cancer therapy. Clin. Lung
Cancer 10(Suppl. 1), S17-S23.
12. Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S,
Ruttinger D, et al. (2010) Highly efficient elimination of
colorectal tumor-initiating cells by an EpCAM/CD3-bispecific
antibody engaging human T cells. PLoS One 5(10), e13474.
13. Kontermann RE. (2010) Alternative antibody formats. Curr.
Opin. Mol. Ther. 12(2), 176-183.
14. Muller D, KontermannRE. (2010) Bispecific antibodies for cancer
immunotherapy: current perspectives. BioDrugs 24(2), 89-98.
15. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW,
Presta LG, et al. (1998) An efficient route to human bispecific
IgG. Nature Biotechnol. 16(7), 677-681.
16. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al.
(2010) SEEDbodies: fusion proteins based on strand-exchange
engineered domain (SEED) CH3 heterodimers in an Fc ana-
logue platform for asymmetric binders or immunofusions and
bispecific antibodies. Protein Eng. Des. Sel. 23(4), 195-202.
17. Seimetz D, Lindhofer H, Bokemeyer C. (2010) Development
and approval of the trifunctional antibody catumaxomab (anti-
EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Cancer Treat. Rev. 36(6), 458-467.
18. Baeuerle PA, Kufer P, Bargou R. (2009) BiTE: Teaching
antibodies to engage T-cells for cancer therapy. Curr. Opin.
Mol. Ther. 11(1), 22-30.
1. Halaby DM, Poupon A, Mornon J. (1999) The immuno-
globulin fold family: sequence analysis and 3D structure
comparisons. Protein Eng. 12(7), 563-571.
2. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woi-
setschlager M, Antes B, et al. (2010) Introducing antigen-
binding sites in structural loops of immunoglobulin constant
domains: Fc fragments with engineered HER2/neu-binding
sites and antibody properties. Protein Eng. Des. Sel. 23(4),
289-297.
3. Landau M, Mayrose I, Rosenberg Y, Glaser F, Martz E, Pupko
T, et al. (2005) ConSurf 2005: the projection of evolutionary
conservation scores of residues on protein structures. Nucleic
Acids Res. 33(Web Server issue), W299-302.
4. Coley AM, Gupta A, Murphy VJ, Bai T, Kim H, Foley M, et al.
(2007) Structure of the malaria antigen AMA1 in complex with
a growth-inhibitory antibody. PLoS Pathog. 3(9), 1308-1319.
5. Ruiz M, Lefranc MP. (2002). IMGT gene identification and
Colliers de Perles of human immunoglobulins with known 3D
structures. Immunogenetics 53(10-11), 857-883.
6. Boder ET, Wittrup KD. (1997) Yeast surface display for
screening combinatorial polypeptide libraries. Nat. Biotech-
nol. 15(6), 553-557.
7. Coiffier B. (2007) Rituximab therapy in malignant lymphoma.
Oncogene 26(25), 3603-3613.
8. Perez EA, Palmieri FM, Brock SM. (2009) Trastuzumab.
Cancer Treat. Res. 151, 181-196.
9. Canon J, Bryant R, Roudier M, Osgood T, Jones J, Miller R,
Coxon A, et al. (2010) Inhibition of RANKL increases the anti-
tumor effect of the EGFR inhibitor panitumumab in a murine
model of bone metastasis. Bone 46(6), 1613-1619.